

# Annual Report

## 2023

The central resource for  
the Swiss biotech industry



## Impressum

Publisher: Swiss Biotech Association  
Concept and text: Sabine Bamert, Michael Altorfer, Swiss Biotech Association  
Layout: Thomas Schicker Konzeption und Gestaltung, Zürich  
Pictures: Swiss Biotech Association  
Print: Schmid-Fehr AG  
Climate-neutral print on wood-free, matt coated paper



# Contents

Swiss biotech industry – Spring feelings	4
Rapid association growth and Orbit talent platform launch	5
Highlights of the Swiss Biotech Association in 2023	6
Swiss Biotech Ventures: Financing and partnering	8
Swiss Biotech Orbit: Matching talent and opportunities	9
Development in numbers	10
The Swiss Biotech Association's mission	11
Swiss Biotech Success Stories	12
Award winners 2019 – 2023	14
Open up your network	17
In the media	18
Digital platforms and publications	20
Partner network	22
Financial statements 2023	24
Our members	27
Preferential business solutions for our members	32
Swiss Biotech Association board and management	34
Supporting the Swiss biotech hub: Objectives 2024	36

## Swiss biotech industry – Spring feelings



**After the challenging “biotech winter”, as clouds clear, my optimism surges. Last year demanded tough choices for our programs, employees, and companies’ fates. By late 2023, positive signals emerged – improved capital markets, multiple acquisitions and partnering deal flow. These signs of “spring” fuel my optimism for the year ahead. The work we do as an industry matters for patients and for Switzerland!**

The pressure on the industry continued globally over the entire last year. Low valuations on the public market impacted private and venture investors, making deals more difficult and valuations lower. As 2023 drew to a close, a ray of hope illuminated the horizon, with financings being finalized and deals being sealed.

In Switzerland, we saw some encouraging and impressive financing rounds, including AC Immune, Alentis, BioVersys, MoonLake, NewBiologix, Noema, Nouscom, Oculis and Tolremo, all raising capital to fund their programs. Idorsia partnered with Sosei Heptares, licensing out Asian rights to crossfinance their pipeline. VectivBio was acquired by Ironwood and T3 by Boehringer Ingelheim, a testament to their progress and potential.

On a global level, the ground breaking success of GLP-1 analogues are noteworthy, with forecasted US sales exceeding USD 100 bn over time for the GLP-1 category (JPM estimate), raising the question of how our healthcare systems will be able to cope.

In oncology, the antibody-drug conjugates seem to be at the height of success, with several prominent takeovers, including Pfizer acquiring Seattle Genetics for more than USD 30 bn, AbbVie taking out ImmunoGen for over USD 10 bn and many more deals.

An upcoming trend seems to revolve around targeted radiotherapy. Novartis has pioneered this space, initiated with the acquisitions of Advanced Accelerator Applications and Endocyte, leading to successful

programs in prostate cancer and making radio therapy a key internal investment focus. Other pharma companies are entering the space with acquisitions, including Eli Lilly agreeing to buy POINT Biopharma and Bristol Myers Squibb acquiring RayzeBio.

At the Swiss Biotech Association, we are continuously broadening the support of our members to add more momentum to this positive trend. To empower biotech companies, and to enhance our reach and reputation, we are expanding our focus on specific vertical industry topics: Our financing vertical is designed for CFOs to foster best practices in fundraising. The talent vertical is geared towards HR professionals, to identify and develop the experts required in our industry. Collaborating with Swissmedic, our medical & regulatory vertical supports local medical development programs. Lastly, our social impact vertical is dedicated to anchoring our beneficial endeavors in society.

We are looking forward to a successful year ahead and love to welcome you at the Swiss Biotech Day on April 22-23 to provide you with more insights and updates on our efforts to drive the success of the Swiss biotech industry.

Sincerely yours,



Patrick Amstutz  
President Swiss Biotech Association



## Rapid association growth and Orbit talent platform launch



**The Swiss biotech industry continued to expand in 2023, we reached a record high of 523 members and the Swiss Biotech Day grew by another 50%. The Swiss Biotech Association continues to support the development of the industry; most notably with the creation of a new talent platform, Swiss Biotech Orbit, two new association chapters and recently introduced peer-to-peer meetings for CFOs and HR leaders.**

While the funding environment remained challenging for listed biotech companies, Switzerland benefited from the fact that over 95% of its biotech companies are privately financed. As outlined in our 2023 Swiss Biotech Report, Swiss biotech companies attracted over CHF 1.3. billion, exceeding the funding levels of 2019, while at the same time investing a record CHF 2.7 billion into their R&D projects.

From the perspective of the Swiss Biotech Association, 2023 was another very successful year:

- ▶ 119 new members joined the Swiss Biotech Association in 2023 alone: Our membership base grew to a record level of 523
- ▶ The Swiss Biotech Day grew by 50%, attracting some 1,800 participants from over 40 countries. Close to 40% of the participants joined us from abroad.

The ongoing expansion of the membership base signifies the trust and support the association enjoys and it also strengthens our credibility with policy makers and international partners. It gives us greater financial flexibility and enables us to have a greater impact when it comes to supporting the Swiss biotech hub.

In 2023 we used this support to:

- ✓ Launch the Swiss Biotech Orbit talent platform and further expand the established Swiss Biotech Directory and Swiss Biotech Ventures platform
- ✓ Launch the new association chapters 'diagnostics and lab automation' and 'industrial biotech'

- ✓ Launch the peer-to-peer networking meetings for Swiss biotech CFOs and HR leaders
- ✓ Expand the Swiss Biotech Association team: Maximilien Murone joined as the contact for Liaison Basel, Northwestern Switzerland, and for the Swiss Biotech Ventures platform; Tiziana Rosa for the Liaison Svizzera Italiana and head of international relations; Natasha Konstantinova leads the launch of Swiss Biotech Orbit and our Association's Academy; and Rachel Ougier further optimizes the business processes and IT infrastructure
- ✓ Provide strong advocacy through our collaborations with Interpharma, science-industries, economiesuisse and the International Council of Biotech Associations
- ✓ Promote the value and contribution of the Swiss biotech industry. The great contributions of Humabs Biomed and Sophia Genetics were honored with the Swiss Biotech Success Stories Award

Our objectives for 2024 are outlined on pages 36–37. Please reach out to our board members and the management team (p. 34–35) with your feedback and support us in providing a strong voice for the Swiss biotech ecosystem.

Yours faithfully,

Michael Altorfer  
CEO

## Highlights of the Swiss Biotech Association in 2023



We commemorated the **Swiss Biotech Association's 25-year anniversary** by showcasing innovations highlights from the past quarter-century, culminating in a special ceremony at the Swiss Biotech Day.



**The Swiss Biotech Day** has developed into one of the leading global biotech collaboration conferences and attracted a record number of more than 1,800 participants from 44 countries. Many international biotech delegations used the Global Village to strengthen their ties with the Swiss biotech hub.

At a **Swiss Biotech Insight** event we looked into early medical launch planning, and how to unlock commercial success.

**The Swiss Biotech Report 2023**, our flagship publication, outlined capital investments in Swiss biotech of CHF 1.3 billion and R&D investments aggregating to CHF 2.7 billion.

Switzerland's most comprehensive **Swiss Biotech Directory** with around 1,300 company entries was printed and distributed to stakeholders.



We represented the Swiss biotech industry in the International Council of Biotechnology Associations' (ICBA) **talks with the WHO and WTO** on the needed reliable IP protection for science-based innovation (e.g. TRIPS waiver discussions, pandemic preparedness).



**Powerful biotech networking platforms** were further enhanced: Swiss Biotech Ventures for financing and partnering, Global Village for international collaboration, and Swiss Biotech Orbit to support the search for talent.

Swiss biotechs and the association were presented in the **Swiss pavilions at BIO International and the BIO Europe** conventions, at the Sachs Associates' investor conferences, the Investment Summit together with Switzerland Global Enterprise, Illmac, and many more.



**Peer-to-peer meetings with biotech CFOs and HR leaders** were launched, and will continue to complement the CEO meetings to collaboratively shape the ideal framework conditions for executives to exchange with their peers, set priorities and address strategic questions.

**The Swiss Biotech Association team grows further:**

In 2023, four new colleagues joined the team (p. 35) to increase our impact in all Swiss regions and internationally.

# Swiss Biotech Ventures: Financing and partnering

**Swiss biotech companies, global biotech investors and industry partners equally benefit from the Swiss Biotech Ventures platform. It is free of charge and matches Swiss biotech companies, global biotech investors, and industry partners to facilitate financing, licensing and research collaborations.**

With the Swiss Biotech Ventures platform, the Swiss Biotech Association enables Swiss biotech companies to present their investment and partnership opportunities to global biotech investors and multinational pharma and industry partners. Investors, family offices, foundations and pharmaceutical companies gain insight into the pipeline of the Swiss biotech hub, and easily discover and contact companies matching their strategic focus based on modalities, indications, and development stage.

Launched in 2021, Swiss Biotech Ventures has developed into a comprehensive database that creates transparency between stakeholders. On the “sell side”, Swiss biotech companies describe their value proposition. On the “buy side”, global biotech investors and pharmaceutical representatives identify investment and partnership opportunities matching with their selection criteria. Both sides present their focus and goals, rendering matchmaking between these players efficient and transparent.

Swiss Biotech Ventures is steadily growing. At the beginning of 2024, more than 800 investors and pharmaceutical companies were listed, and about 200 innovative venture projects from Swiss biotech companies were presented. Every time a venture matching the selection criteria of an investor is added, or its status changes (e.g. from preclinical to clinical phase I), interested parties receive an email notification and can find out more on the platform.

Both sides gain valuable time as individual communication on the project development is replaced by timely, transparent and consistent information. In the Swiss tradition, the Swiss Biotech Association takes a neutral stance. No company is promoted,

nor privileged information is shared with any of the parties, nor does the Swiss Biotech Association receive any success fee. Anyone on the platform has free access to identical information, simultaneously, transparently and to the benefit of all parties.

In conjunction with the Swiss Biotech Ventures platform, the Swiss Biotech Association also helps companies to present and partner at the Swiss Biotech Day and at national and international events. Quarterly highlight reports from the Swiss biotech industry with background information complete the offering.

**SWISS+**  
**BIOTECH™**  
Ventures

## Join Swiss Biotech Ventures and gain access to:

- ▶ free of charge platform, by invitation only
- ▶ matching Swiss biotech companies with global biotech investors and industry partners to facilitate financing, licensing and research collaboration
- ▶ timely, transparent, simultaneous, and consistent information
- ▶ a steadily growing database of thriving biotech ventures
- ▶ free newsletters on Swiss biotech venture highlights and background information



Use this QR code to register on Swiss Biotech Ventures and promote the platform amongst your peers around the globe



# Swiss Biotech Orbit: Matching talent and opportunities



## Bridging talents to biotech brilliance

In 2022, the Swiss Biotech Association launched a pilot digital platform to offer support to Ukrainian citizens and other nationalities eligible for protection status S in Switzerland, helping them to identify suitable job opportunities in our industry.

Today, the Orbit platform has an exiting talent pool of graduates from business schools and universities, PhD and PostDoc, and experienced biotech professionals who are interested in careers in the Swiss biotech and life science industry.

Swiss Biotech Orbit helps to match job opportunities and talents, and supports all Swiss biotech companies that can offer job opportunities.



## Rapidly expanding

The non-public Swiss Biotech Orbit talent platform matches the skills of talents with the criteria of job offers. Since its launch, numerous life science companies and talents have joined, and more are joining every day, contributing to the rapid expansion of the platform.

Swiss Biotech Orbit opens doors to exciting opportunities for professionals, and future talents in life sciences R&D, and supports Swiss biotech companies in identifying the right talent in the industry.



## How to get involved

Swiss Biotech Orbit can only be successful with the support of our members and other stakeholders in the industry. We encourage all our members and partners to join Swiss Biotech Orbit and contribute to the growth of the life science industry in Switzerland.



Use this QR code to match talents and opportunities

## Development in numbers

At the end of 2023, the Swiss Biotech Association counted 523 members. Our website, newsletters, social media activities, and mailings provide an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry. The number of members, subscribers and website visitors is steadily increasing.



# The Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access

to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.



## Our mission

**The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.**

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation. To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

### **Developing favorable and competitive framework conditions**

- ▶ Creating awareness of the biotech industry's needs and interests with policy makers
- ▶ Advocating a competitive tax system alongside lean and pragmatic regulations
- ▶ Fostering life science education, technology transfer and intellectual property

### **Attracting talent, know-how and financial resources to drive innovation and growth**

- ▶ Promoting and facilitating access to funding opportunities
- ▶ Connecting investors and attractive biotech investment opportunities
- ▶ Facilitating access to national and international talent

### **Fostering networking through strategic, national and international partnerships**

- ▶ Connecting industry stakeholders and life science clusters
- ▶ Organizing and co-promoting national and international life science events
- ▶ Providing access to privileged information through industry platforms and working groups

### **Promoting the accomplishments of the Swiss biotech industry**

- ▶ Disseminating the value-creation of Swiss biotech companies
- ▶ Visualizing the diversity and competitiveness of Swiss biotech companies
- ▶ Presenting innovative products and technologies and their contribution to quality of life



# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

## Swiss Biotech Success Stories demonstrate the power and potential of the industry

**The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.**



Switzerland is one of the world's leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 50,000 jobs and, together with the pharmaceutical and chemical industries, accounts for almost half of Swiss exports.

To make the industry's impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational,

medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

"It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive," says Michael Altorfer, CEO of the Swiss Biotech Association. "Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech."

### 12 success categories

- ▶ Completed achievement with lasting impact
- ▶ Scientific breakthrough
- ▶ New technology
- ▶ Strong impact on society
- ▶ Product approval and sustainable revenues
- ▶ Important IP, innovative deal-making, acquisition
- ▶ Involvement of one or more Swiss citizens
- ▶ Swiss-based company / institution
- ▶ Creation of jobs in Switzerland
- ▶ Other aspect with a direct link to Switzerland
- ▶ Enabler for the biotech industry
- ▶ Swissness: Think global, made in Switzerland



**Luca Bolliger**  
President of the jury  
Vice President  
Swiss Biotech  
Association



**Patrick Aebischer**  
Entrepreneur  
Former President  
of EPFL



**Stefanie Flückiger-  
Mangual**  
Chief Executive Officer  
and Co-Founder Tolremo



**Gabrielle Gache**  
Head of Business  
Development (EMEA)  
Santen Pharmaceutical



**Seraina Gross**  
Business journalist  
Handelszeitung



**Chandra P. Leo**  
Investment Advisor  
Private Equity  
HBM Partners



**Daniela Marino**  
Chief Executive Officer  
and Co-Founder Cutiss



**Jürg Zürcher**  
Independent biotech-  
nology leader and  
expert



**Thomas Staffelbach**  
Secretary of the jury  
TS Kommunikation

A big thank you to our

Sponsors



The Swiss Biotech Success Stories Awards are also supported by



| Basel-Stadt | TS Kommunikation

# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



- ▶ Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.

## BACHEM

- ▶ Bachem is a leading manufacturer of peptides and oligonucleotides. The company has grown over 50% in the last five years and now offers more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides. Its investment plans call for the investment of over USD 400M to continue to pursue its growth strategy.



- ▶ Basilea Pharmaceutica is a leader in targeted oncology small molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has launched two anti-infective treatments: Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole), an antibiotic for severe hospital bacterial infections.



- ▶ Biogen in Baar is a leading biotechnology company that pioneers innovative science and delivers new medicines to transform patient's lives. A broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy and the state-of-the-art biologics manufacturing facility in Luterbach are proof of Biogen's pioneering approach.



- ▶ Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to business partners globally. Over a million patients benefit from their therapies every year.



- ▶ ESBATEch, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATEch platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.



## Etienne Jornod



- ▶ Etienne Jornod, Swiss entrepreneur, was Executive Chairman of the Vifor-Galenica Group delivering 25 consecutive double-digit net profit growth, supporting millions of patients and creating thousands of jobs. In 2020, he acquired OM Pharma with friends, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise.



- ▶ Genedata, global market leader for software solutions that digitalize data-rich and complex bio-pharmaceutical R&D processes, enables an R&D revolution driven by precision medicines and artificial intelligence approaches. It helps the industry to deliver innovative biotherapeutics, vaccines and cell & gene therapies faster.



- ▶ The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.



- ▶ Helsinn, an important employer in Ticino, has a broad portfolio of marketed cancer care products and a deep development pipeline. It has built significant R&D and manufacturing capacities, also advances patient care and supports healthcare innovation with its investment fund.



- ▶ Humabs BioMed, subsidiary of Vir Biotechnology, uses its immunologic expertise and cutting-edge technology to combat infectious diseases and other serious conditions. They are a pioneer in the discovery, engineering, and development of human monoclonal antibodies, e.g. crucial for fighting Ebola and COVID-19, and have helped transform the infectious disease landscape.

## Lonza

- ▶ Lonza is one of the world's largest healthcare manufacturing organizations, serving pharmaceutical, biotech and nutritional markets. Lonza's work enables its customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.



# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



- ▶ Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.



- ▶ Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.



- ▶ The advanced technologies in protein expression by Selexis provide biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. Nearly a hundred drug candidates in clinical development and three commercial products utilize the technologies of the Plan-les-Ouates-based company.



- ▶ SOPHiA GENETICS generates clinically actionable insights and improved patient outcomes from a global data-sharing network. They democratize data-driven medicine globally through a cloud-based, decentralized SaaS platform, empowering shared insights among clinicians and researchers, and aiming for equal access to knowledge and improved clinical outcomes.



- ▶ The trio of foundations has been supporting biotech startups with great success for more than 10 years, thereby making a significant contribution to the growth of the Swiss biotech industry. They share the nomination for the Swiss Biotech Success Stories Award.



- ▶ This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.



## Werner Arber



- ▶ Werner Arber, Swiss microbiologist and geneticist, won the 1978 Nobel Prize in Physiology or Medicine for his discovery of restriction endonucleases. His groundbreaking research in the field of molecular genetics was instrumental in the development of biotechnology.



Use this QR code to find more information about the Swiss Biotech Success Stories

## Open up your network

**To ensure that the Swiss Biotech Success Stories will be visible around the globe in many locations, media and events, help us with your network and distribution power.**

Let us know if you have contacts in your network who could benefit from the insight into Swiss Biotech Success Stories, and are curious to learn more about the stunning accomplishments of entrepreneurs in this competitive industry.

Interested parties could be: Your customers, suppliers, partners, a journalist, an investor, your company's communication unit, your follower base on social media, your favorite politician, an event platform dedicated to life science, your rotary club colleagues or any other possibility, that could help to promote these success stories.

Share with us your suggestions for spreading the word by e-mail to [success@swissbiotech.org](mailto:success@swissbiotech.org)



Use the QR code to get to our online form

# In the media

Key articles and interviews mainly in leading Swiss media supported our goal in making sure that the biotech industry got heard in the public. The coverage on Swiss biotech is steadily growing.

## From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs

02 Jun 2023 | INTERVIEWS

## Swiss start-up sets out to lower cost of gene therapy

Swiss start-up NewBiologix believes it can dramatically bring down the cost of gene therapies, typically priced

Mittwoch, 3. Mai 2023 - Nr. 34 Gesundheit FINANZ- u. WIRTSCHAFT | 11

## Biotech-Erfolge gehen an der Börse vorbei

MEDIKAMENTEN-ENTWICKLUNG Schweizer Unternehmen haben an bahnbrechenden Anwendungen mitgearbeitet, Anleger profitieren nur selten.

**ROBERT BETHANIAN**

Der Biotech-Branche hat Ende 2022 gegenüber dem Vorjahr einen Umsatzanstieg von 10,5 Prozent verzeichnen können. Die Umsatzerlöse sind jedoch um 1,5 Prozent gesunken. Der Umsatzanstieg ist vor allem auf den Erfolg von Moderna zurückzuführen, die im vergangenen Jahr einen Umsatz von 1,3 Milliarden US-Dollar erzielt hat. Die Umsatzerlöse sind jedoch um 1,5 Prozent gesunken. Der Umsatzanstieg ist vor allem auf den Erfolg von Moderna zurückzuführen, die im vergangenen Jahr einen Umsatz von 1,3 Milliarden US-Dollar erzielt hat.

1 Kapitalflüsse in Schweizer Biotech

2 Angewandte Biomolekulare Chemie

## Fostering international alliances

**PARTNERING** The Swiss Biotech Day 2023 was the biggest and most international edition so far, demonstrating the strengths and global reach of the Swiss biotech hub. Its Global Village platform for international delegations supports the event's role as a truly global biotech networking event.

## Biotech leads science growth boost for Switzerland

**BUSINESS**

## Investitionen und Wachstum in global schwierigem Umfeld

Die Schweizer Biotechnologie-Branche hat 2022 Widerstandsfähigkeit bewiesen und ihre Rolle als wichtiger Innovationsmotor für das globale Gesundheitswesen bestätigt. Obwohl sich das Investitionsklima deutlich verschlechterte, konnten die Schweizer Biotechfirmen globale Investoren auch im vergangenen Jahr von der Innovationskraft ihrer Projekte überzeugen. Insgesamt brachten die Biotech-Startups und KAVs mehr als 1,3 Mrd. Franken zu. Dies war zwar deutlich weniger als in den beiden Rekordjahren während der Covid-Pandemie, lag aber über dem Niveau von 2019. Im Vergleich zu anderen führenden Biotech-Hubs profitierte die Schweiz davon, dass mehr als 97% der Schweizer Biotechfirmen privat finanziert sind. So konnten zum Beispiel CTR Life und ImmunOn Therapeutics Kapitalerhebungen von über 70 Mio. Franken realisieren. Aber auch einige börsennotierte Firmen verstärkten ihre Kapitalreserven trotz des angespannten Biotechmarktes erfolgreich. So brachten etwa VertexBio, ADC Therapeutics oder MoonLake Immunotherapeutics dreistellige Millionenbeträge zu.

**Dr. Michael Altörfer**

BIOTECHNOLOGIE

## Schweizer Biotechbranche spürt 2022 zurückhaltende Investitionsbereitschaft

## 'AGEFI

Moins de capitaux levés, mais une série de records pour la biotech suisse en 2022



Save the date!

# SWISS BIOTECH DAY 2025

© Swiss Biotech Association

May 5–6, 2025  
Congress Center Basel

## What you can expect:

- › Meet 1,800+ senior experts from the life science industry
- › 100+ exhibitors and Global Village with international delegations from all over the world
- › Swiss Biotech Success Stories Awards
- › Innovative biotech start-ups and medium-sized biotech companies
- › Thematic company pitching sessions
- › Thematically focused panel discussions
- › Swiss Biotech Report 2024
- › Pre-scheduled one-to-one partnering meetings
- › General Assembly of the Swiss Biotech Association



Sign in on our website at  
[swissbiotechday.ch](https://swissbiotechday.ch)  
and stay updated about any news.

Media partners:

**|transkript**

 **European  
Biotechnology**  
Life Sciences and Industry Magazine

Host:

 **Swiss Biotech  
Association**

# Digital platforms and publications


One of the Swiss Biotech Association's goals is to emphasize the valuable contribution of the biotechnology industry in Switzerland and abroad, and position it as an important value-adding economic pillar. Besides the Swiss Biotech Success Stories (see pages 12–17), our digital platforms and publications support the association's drive to expand its impact and strengthen its role as the central resource for the Swiss biotech industry.

The screenshot displays the Swiss Biotech website interface. At the top, the logo 'SWISS BIOTECH' is visible alongside navigation and user options. The main content area is divided into two sections: 'Industry news' and 'Our featured events & more'. The 'Industry news' section lists several articles, including 'FluoSphera's project is awarded a grant of CHF 1.1 million from Innosuisse', 'CDR-Life: FDA Clearance for treat...', 'Cellestia awarded CHF 2 million...', 'Newron valuation report "A pivot...', 'Oculus: Phase 3 trial of eye drops', and 'The Alzheimer's Drug Discovery Foundation invests USD 4.2M in GilaPharm'. The 'Our featured events & more' section highlights 'Swiss Biotech Pavilion @ BIO-Europe Spring' in Barcelona and 'Swiss Biotech Day and Swiss Biotech Success Stories Awards' in Basel. Overlaid on the right side of the screenshot are three promotional graphics: 'Global Village' with the text 'COLLABORATE WITH SWISS BIOTECHS', 'SWISS BIOTECH Ventures' with 'INVEST IN SWISS BIOTECHS', and 'SWISS BIOTECH Orbit' with 'TALENT MEETS OPPORTUNITIES'.


Swiss Biotech Ventures matches Swiss biotech companies, global biotech investors, and industry partners to facilitate financing, licensing and research collaborations

Swiss Biotech Orbit helps to match job opportunities and talents, and supports all Swiss biotech companies that can offer job opportunities


swissbiotech.org content is a valuable info source for the industry, and provides an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry



With the digital Swiss Biotech Directory the right partner is found fast



Our print publications are distributed at events and by direct mailings



With our monthly newsletter you stay ahead in the dynamic biotech landscape with the latest industry insights and opportunities

## Partner network provides crucial advantages

**The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.**

### **Access to a wider pool of resources**

By partnering with other organizations, we can access a broader range of resources and exchange with specialized industry stakeholders. Our partnerships strengthen our voice and leverage our impact.

### **Increased credibility and visibility**

Collaboration with reputable partners and policy makers increase the credibility and visibility of our association. This builds trust and confidence, and helps to optimize the framework for a successful industry development.

### **Improved information exchange**

Our partners enable us to access and transfer more knowhow, to provide our stakeholders with privileged information, networking opportunities, international connectivity and access to technologies.

### **Amplified support for Swiss biotech ecosystem**

Our partners help promote and improve our platforms and thus accelerate and amplify the support we can provide to the Swiss biotech stakeholders.



Check out  
our partners

**The Swiss Biotech Association can reap several benefits from forming partnerships with other organizations. National and international partnerships help us to leverage our impact.**



▶ **...optimize framework conditions**

Other associations, councils, committees and policy makers

▶ **...attract, educate and retain talent**

Swiss Biotech Orbit platform and Swiss Biotech Association Academy partners

▶ **...foster international collaborations & trade**

International life science clusters, trade agencies, business hubs, and e.g. the Global Village at the Swiss Biotech Day

▶ **...seek and offer preferential conditions for our members**

Equipment suppliers, insurances, event organizers, analysts, scientific publishers

▶ **...promote competitive advantages**

Promotion agencies, chambers of commerce, Swiss Biotech Report



Our  
partnerships  
help to ...

▶ **...increase credibility & visibility of the industry**

Media, Swiss Biotech Day, Swiss Biotech Success Stories, Swiss Biotech Report, international Swiss pavilions

▶ **...facilitate access to funding and partnering**

Swiss Biotech Ventures platform, investors associations, international investment partners

▶ **...link to specialized stakeholders**

Academia, technology transfer organizations, business development experts



## Income statement

In CHF	2023		2022	
	Expenses	Income	Expenses	Income
Membership fees		928,000		853,500
International projects		2,929		3,588
National projects		1,085,780		843,643
Website & community platform		1,400		7,940
Swiss Biotech Success Stories		13,000		5,000
Swiss Biotech Report		58,000		48,000
Swiss Biotech Directory		23,870		27,670
Increase/decrease bad debt provision		-2,000		-8,500
<b>Total income</b>		<b>2,110,979</b>		<b>1,780,841</b>
Fees to other associations	25,476		25,751	
International projects	60,882		49,485	
National projects	1,153,021		877,596	
Swiss Biotech Success Stories	15,615		14,285	
Increase/decrease tied capital "Swiss Biotech Success Stories"	-2,000		-5,000	
Swiss Biotech Sounding Board	0		0	
Increase/decrease tied capital "Swiss Biotech Sounding Board"	0		0	
Swiss Biotech Report	73,079		65,247	
Swiss Biotech Directory	32,150		39,145	
Website & community platform	82,735		45,112	
<b>Association activities expense</b>	<b>1,440,958</b>		<b>1,111,621</b>	
Management fees <sup>1</sup>	329,548		375,454	
Accounting & member support	167,399		168,326	
Office rent & administration	32,436		23,220	
Consulting	7,398		5,991	
Public relations	112,652		69,144	
<b>Other operating expenses</b>	<b>649,434</b>		<b>642,135</b>	
<b>Financial income result</b>		<b>8,943</b>		<b>8,429</b>
<b>Income from previous reporting periods</b>		<b>0</b>		<b>0</b>
<b>Tax expenses</b>		<b>234</b>		<b>167</b>
<b>Net profit for the year</b>		<b>11,410</b>		<b>18,489</b>

<sup>1</sup> Management fees related to events and promotional products are directly booked to the respective project

## Balance sheet

In CHF	Balance Sheet 31.12.2023		Balance Sheet 31.12.2022	
	Assets	Liabilities	Assets	Liabilities
<b>Assets</b>				
Cash and cash equivalents	263,206		312,436	
Accounts receivable	20,385		61,512	
Accrued income & prepaid expenses	80,370		42,758	
<b>Total assets</b>	<b>363,961</b>		<b>416,706</b>	
<b>Liabilities and equity</b>				
Accounts payable		113,523		147,818
Accrued expenses & deferred income		57,040		84,900
Association equity		131,239		131,239
Tied capital for SBA Success Stories		3,000		5,000
Tied capital for SBA Sounding Board		10,000		10,000
Retained earnings		37,750		19,261
Net result of the year		11,410		18,489
<b>Total liabilities and equity</b>		<b>363,961</b>		<b>416,706</b>



# Auditor's report



Phone +41 44 444 35 55  
www.bdo.ch

BDO Ltd  
Schiffbaustrasse 2  
8031 Zurich

## Report of the statutory auditor on the limited statutory examination to the general meeting of

### Swiss Biotech Association (SBA), Zurich

As statutory auditor, we have examined the financial statements (balance sheet, income statement and notes) of Swiss Biotech Association (SBA) for the financial year ended 31 December 2023.

These financial statements are the responsibility of the association board. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of inquiries of company personnel and analytical procedures as well as detailed tests of company documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the articles of association.

Zurich, 2. February 2024

BDO Ltd

Manuel Lüthi

Licensed Audit Expert

ppa. Christine Gundi  
Auditor in Charge  
Licensed Audit Expert

**Enclosure**  
Financial statements

3B Biotech Research Sagl	Auregen Biotherapeutics SA	Celonic AG
3T Biosciences Europe GmbH	Avance Basel GmbH	Cerbios-Pharma SA
4G Clinical B.V.	Avrion Therapeutics AG	Cerdia International GmbH
7AlpsBio GmbH	Axon Lab AG	certus molecular diagnostics ag
AB2 Bio Ltd	<b>Azafaros Switzerland AG</b>	Cetacea Consulting GmbH
<b>abc biopply AG</b>	Baccinex SA	Chemgineering Switzerland AG
abcDNA GmbH	Bachem AG	<b>Chinsiders GmbH</b>
ABCDx SA	BakerHicks AG	Choose Life BioTech SA
Abologix Sàrl	Baliopharm AG	Cilatus Biopharma Consulting AG
AC Bioscience SA	Basilea Pharmaceutica Ltd.	CimArk SA
AC Immune SA	Bavarian Nordic Berna GmbH	Cimeio Therapeutics AG
ACM Biosciences AG	BC Platforms AG	CIS Biopharma AG
ACROBiosystems AG	Becton Dickinson AG	Citeline
Acthera Therapeutics AG	BERNINA Biolinvest AG	<b>Clear Solutions Laboratories AG</b>
Activen SA	BIDECO AG	ClearView Healthcare Partners Switzerland GmbH
ADC Therapeutics SA	BigOmics Analytics SA	GmbH
Addex Therapeutics Ltd	Bio-Rad Laboratories AG	Clinipace AG
Adienne Pharma & Biotech SA	Bio-Technopark Schlieren-Zürich	ClinOps Advisory Turner GmbH
Adiposs SA	<b>BioArk SA</b>	Connectors Verbindungstechnik AG
Adolf Kühner AG	BioConcept AG	Coulter Partners
Adoram Therapeutics SA	BioCopy AG	CRB Group GmbH
Advanced Clinical Switzerland GmbH	Bioengineering AG	Creoptix AG
Advitech Advisory and Technologies SA	Biogen International GmbH	CROSS Research SA - CROss Alliance®
Affivant Sciences GmbH	BioLingus	CSEM
<b>aiNET GmbH</b>	BioMedPartners AG	CSL Behring
<b>Akceso Advisors AG</b>	<b>BiomedVC AG</b>	CTC Resourcing Solutions AG
Alentis Therapeutics AG	Bionter AG	Culture Collection of Switzerland AG
Alitheia Genomics SA	Biopôle SA	<b>Curare Swiss AG</b>
Alloy Therapeutics (Switzerland) AG	Biosynth Carbosynth	Curatis AG
<b>AlphaOnco Swiss SA</b>	BioVersys AG	<b>Cureline AG</b>
Alphastrat GmbH	BISC Global GmbH	<b>Curio Biotech SA</b>
Altasciences	blsc - bihlmann life science communication	CUTISS AG
<b>Altorfer Engineering GmbH</b>	<b>Blueprint Medicines (Switzerland) GmbH</b>	Cytiva Europe GmbH
AlveoliX AG	<b>Boehler Life Science Advice</b>	Cytosurge AG
Amal Therapeutics	Bonetti & Partner GmbH	Cyxone Switzerland AG
<b>Amazentis SA</b>	Bright Peak Therapeutics AG	D36.ch Sàrl
<b>Amphilix AG</b>	Bromatech (Suisse) SA	Dao Tun GmbH
AMYRA Biotech AG	Bucher Biotec AG	Debiopharm International SA
AnaPath Services GmbH	Büchi AG	Deep Breath Intelligence AG
Anaveon AG	Bühlmann Laboratories AG	<b>Delta Medical Promotions AG</b>
Anjarium Biosciences AG	C-CIT Sensors AG	Demiurge Technologies AG
anteris Helvetia AG	<b>Caland SA</b>	diaxxo AG
<b>Antion Biosciences SA</b>	Calliditas Therapeutics Suisse SA	Dimericon Therapeutics AG
<b>Aphaia Pharma AG</b>	Calypto Biotech SA	Dinaqor AG
<b>Apricot Therapeutics AG</b>	Cancer Research and Biotechnology AG	DPS Engineering Switzerland GmbH
ApTissen SA	Canlion AG	DrM, Dr. Mueller AG
Araaris Biotech AG	<b>CanSino Biologics (Switzerland) SA</b>	<b>EAI Europe AG</b>
<b>Ariceum International AG</b>	CanVirex AG	EffRx Pharmaceuticals SA
Artam GmbH	Capama AG	Elthera AG
ARTIDIS AG	Carbogen Amcis AG	<b>Encentrio Therapeutics International GmbH</b>
ASC Oncology Schweiz AG	Catalent Pharma Solutions GmbH	<b>Endogena Therapeutics</b>
Asceneuron SA	Catalyze Switzerland GmbH	EraCal Therapeutics Ltd
Assystem Care	CDR-Life AG	EspeRare Fondation
<b>Asterivir SA</b>	CEBIS International	Eurofins BioPharma Product Testing Switzerland AG
<b>Astra Therapeutics</b>	<b>Ceidos SA</b>	Switzerland AG
Athebio AG	Celerion Switzerland AG	Eurofins Genomics
<b>ATLyphe AG</b>	Cellestia Biotech AG	Eviden AG
Aukera Therapeutics GmbH	<b>CELLnTEC advanced cell systems AG</b>	Evitria AG
Aurealis Therapeutics AG	cellvie AG	ExcellGene SA

ExpertInova AG	Incaptek Sàrl	Maxia Strategies GmbH
F. Hoffmann-La Roche AG	InCephalo AG	MaxWell Biosystems AG
<b>FABLE GmbH</b>	Incyte Biosciences International Sàrl	MD Bioproducts GmbH
<b>FB Global Regulatory Consulting and Coaching</b>	<b>Infinity Communications Sàrl</b>	Med Discovery SA
<b>FimmCyte AG</b>	Infors HT Schweiz	MEDExpansion Sàrl
<b>FinalSpark SARL</b>	<b>InkVivo Technologies AG</b>	Medical Trials Analysis Swiss SA
<b>Fischer PreclinTox Consulting</b>	InnoMedica Holding AG	<b>MedScienceSwiss AG</b>
<b>Floratek Pharma SA</b>	Innovative Sensor Technology AG	<b>MedXCell SA</b>
FluoSphera SA	INOFEA AG	Memo Therapeutics AG
<b>Fortrea Switzerland AG</b>	InsideReg Sarl	<b>Menarini Biotech srl</b>
<b>Forty51 Advisors AG</b>	InSphero AG	Merz/Anteis SA
<b>FoRx Therapeutics AG</b>	Integra Biosciences AG	MesenFlow Technologies Sàrl
Fritz Gyger AG	Integrated Biologix GmbH	<b>metaShape Pharma AG</b>
Future Health Pharma GmbH	<b>Integrated Project Services GmbH</b>	MetrioPharm AG
G&L Scientific (Schweiz) GmbH	<b>IntelDrug Consulting Pospišil</b>	Micros Pharmaceuticals AG
<b>Galapagos GmbH</b>	InterAx Biotech AG	Micro-Sphere S.A.
Galsler SA	Inthera Bioscience AG	Microsynth AG
<b>GBC-HpVac SA</b>	Invasight AG	Miltenyi Biotec Swiss AG
GBiotech Sàrl	IONctura SA	<b>MOD1 AG</b>
Genedata AG	IPS Biopharma AG	Molecular Partners AG
<b>Genesupport SA</b>	IQOne Healthcare Switzerland SA	Monte Rosa Therapeutics AG
GeNeuro SA	IQVIA AG	<b>Moonlight AI Sàrl</b>
GenSearch Switzerland	<b>Isospec Analytics SA</b>	Mosanna Therapeutics AG
GliaPharm SA	Jacobs Switzerland GmbH	<b>MPC Therapeutics SA</b>
GlycoEra AG	Jagotec AG - Vectura Fertin Pharma	<b>MRGN Advisors Sàrl</b>
GMT Fine Chemicals SA	JfG Life Sciences Stiftung der Universität Basel	MUVON Therapeutics AG
Gnubiotics Sciences Sàrl	JMP Software, SAS Institute GmbH	MV BioTherapeutics SA
Granite Bio AG	<b>Kabuto SA</b>	Mymetics SA
<b>Griffon Pharmaceuticals International SA</b>	Kinarus Therapeutics AG	Myovant Sciences GmbH
GT Gain Therapeutics SA	<b>Kisco Sarl</b>	Nagi Bioscience SA
<b>GXP CONSULTING Switzerland GmbH</b>	KPMG AG	<b>Nathalie Jenni Consulting GmbH</b>
<b>GxpManager</b>	KVALITO AG	Navignostics AG
Haya Therapeutics SA	Labatec Pharma SA	NBE-Therapeutics AG
HBM Partners AG	Labcorp Central Laboratory Services Sàrl	<b>NCMA Consulting GmbH</b>
headcount AG	<b>LabForce AG</b>	NDA Regulatory Service Switzerland GmbH
Healiva SA	Laevoroc Oncology AG	<b>NegotiumBio Schweiz GmbH</b>
Health Advances GmbH	LaForce Business Solutions Sagl	Nemis Technologies AG
Healthcon AG	LAGOSTA SA	Neovii Pharmaceuticals AG
<b>HekeTiss SA</b>	<b>LaRive Bio AG</b>	Neurimmune AG
Helsinn Healthcare SA	LATAM Pharma Innovative Ventures AG	<b>Newbiologix SA</b>
Helvetica Biotech Sarl	Laves-Arzneimittel GmbH	Nexco Analytics Sarl
Helvetica Health Care Sàrl	leadXpro AG	<b>NexMR GmbH</b>
HEMEX AG	Legacy Healthcare (Switzerland) SA	Nice & Green SA
HemostOD SA	<b>Leman Biotech Lausanne SA</b>	NLS Pharmaceuticals AG
Hengrui Europe Biosciences AG	Life Sciences Executive Search	Nodes Advisors AG
HGF GmbH	Light Chain Bioscience - NovImmune SA	Noema Pharma AG
<b>Hoffmann &amp; Partner AG</b>	LimmaTech Biologics AG	<b>Nouscom AG</b>
Homburger AG	Limula SA	NovaGo Therapeutics AG
House of Lab Science AG	Linkster Therapeutics AG	Novaremed AG
Humabs BioMed AG	Lino Biotech AG	Novartis Pharma AG
Hyperbolic Holdings GmbH	Lonza AG	Novigenix SA
Ichnos Sciences SA	LS Instruments AG	Novochizol SA
ICON Clinical Research (Switzerland) GmbH	LubioScience GmbH	Numab Therapeutics AG
<b>iCure SA</b>	Lucerna Chem AG	NXI Therapeutics AG
Ideogen AG	Lunaphore Technologies SA	ObsEva SA
Idorsia Pharmaceuticals Ltd.	LYO-X AG	OCCIDENT Group AG
IE Life Science Engineering AG	Malcisbo AG	Oculus Operations Sarl
ImmunOs Therapeutics AG	Matterhorn Biosciences AG	Oculox Technologies SA
		<b>Ogram SA</b>

OM Pharma Ltd  
OMNI Life Science GmbH  
Omya International AG  
Oncodesign Services  
**Onena Medicines AG**  
**ONtrack Biomedical AG**  
Onward Therapeutics SA  
oprandi & partner romandie sa  
Oriento SA  
**Orio Therapeutics SA**  
Orion Biotechnology Switzerland  
**Oryl Photonics SA**  
**Otten Life Sciences Consulting Sàrl**  
P&G MedChem AG  
Pall (Schweiz) GmbH  
PAREXEL International (CH) AG  
PDC Therapeutics SA  
Peleven AG  
**PeptART Bioscience GmbH**  
Peptone Switzerland AG  
Perseo Pharma AG  
Phargentis SA  
Pharma-Consulting ENABLE GmbH  
PharmaBiome AG  
PharmNDev Experts SA  
Pharvaris GmbH  
Pheida AG  
Philochem AG  
Pilatus Biosciences SA  
Planetary SA  
plusbiome AG  
PLX Healthcare Services (Switzerland) AG  
**PMS Process Management System**  
**Polaroid Therapeutics**  
PolyPeptide Group AG  
**Porton Pharmaceutical Chemicals GmbH**  
Praed Pharmaceuticals Ltd  
PreComb Therapeutics AG  
Promega AG  
ProteomeDiX AG  
**Provectis Helathcare AG**  
PSI CRO AG  
Pureos Bioventures  
Purple Biotech GmbH  
**Qanatpharma AG**  
QBDC GmbH  
**Qiào Advisors GmbH**  
Quartz Bio SA  
Quercis Pharma AG  
Quotient Suisse SA  
RADAR RP Sàrl  
**Rambam AG**  
**RDP Pharma AG**  
Recolony AG  
**Reconnect Labs AG**  
Recordati AG  
Redbiotec AG  
Regen Lab SA  
Rejuvener Life Sciences AG

**REM Analytics SA**  
Remap Consulting GmbH  
Repertoire Immune Medicines AG  
Resea Biotech GmbH  
Resistell AG  
**RespAct GmbH**  
Rhizen Pharmaceuticals AG  
Ridgeline Discovery GmbH  
Risklick AG  
Rivia SA  
Rowestil Consulting GmbH  
**Sai Life Sciences Ltd**  
Saiba AG  
SAKK  
Salmon Pharma GmbH  
Santersus AG  
Santhera Pharmaceuticals (Switzerland) AG  
Sartorius Stedim Switzerland AG  
Scalyte AG  
**SCG Siam Cement Group**  
Schmidt Versicherungs Treuhand AG  
Seagen International GmbH  
Securecell AG  
**SEED Biosciences SA**  
**Sefunda AG**  
Selexis SA  
**Selmod GmbH**  
Senn Resources AG  
Sferalp SA  
SFL Pharma GmbH  
SGS Analytics Switzerland AG  
SGS Life Sciences Geneva  
Shimadzu Schweiz GmbH  
SICPA SA  
Socorex Isba SA  
**SOLID Drug Development SA**  
**Solvias AG**  
Somagenetix AG  
Sophia Genetics SA  
Sotio Biotech AG  
**SP Groups SA**  
SpacePharma SA  
Spexis AG  
Spinofrin  
Springer Nature Ltd  
STALICLA SA  
Stobbe Pharma GmbH  
Strategy Consulting Dr. Rudolf K. Sprüngli  
Streefkerk Life Sciences Consultancy (SLSC)  
**Stromal Therapeutics AG**  
Superlab Suisse AG  
**Supply Chain Operations SA**  
swati AG  
Swiss Biotech Center SA  
**Swiss Consultant-Network GmbH**  
SwisSolution Human Capital AG  
Switzerland Global Enterprise  
Swizzard Pharma AG  
SynDermix AG

Synndos Therapeutics AG  
Syneos Health Switzerland GmbH  
Synple Chem AG  
T3 Pharmaceuticals AG  
Talisto GmbH  
TargImmune Therapeutics  
ten23 health AG  
**Tenpoint Therapeutics GmbH**  
**The Jackson Laboratory**  
The RSA Group  
therainnova AG  
Thermo Fisher Scientific Biologics Lengnau  
Thermo Fisher Scientific Life Technologies  
Tigen Pharma SA  
Tigermed Swiss AG  
Tissuelabs Sagl  
tiventia AG  
TOLREMO therapeutics AG  
Toopoint for Lab Science  
Topadur Pharma AG  
**Trialize AG**  
**Tridek-One Therapeutics SAS**  
**Trilliume GmbH**  
UCB Pharma AG/UCB Farchim SA  
UPS Healthcare  
**Vaccentis AG**  
Vaderis Therapeutics AG  
valuationLAB AG  
**Vandria SA**  
Vector BioPharma AG  
Venture Valuation  
Versameb AG  
Versantis AG  
**VILS Switzerland GmbH**  
Viopas Venture Consulting GmbH  
**Vir Biotechnology International GmbH**  
VirdisGroup Sàrl  
Virometix AG  
VISCHER AG  
Voisin Consulting Life Sciences  
Volv Global SA  
VTU Engineering Schweiz AG  
Walder Wyss AG  
**Watson-Marlow AG**  
WuXi AppTec  
Wyss Zurich  
Xcenda Switzerland GmbH  
Xenomatrix AG  
Xlife Sciences AG  
Ymmunobio AG  
Yokogawa Innovation Switzerland GmbH  
**YONI Solutions SA**  
YugaCell GmbH  
**Zambon Biotech SA**  
Zeta CH AG

## We enhance the visibility of biotech companies

These members profit from a cost-effective and easy-to-do marketing opportunity. For one year their logos feature on our communication tools. These include the Swiss Biotech Association exhibition booth at renowned conferences, publications, and presentations about the Swiss biotech industry for stakeholders, talents, partners, media, investors, and in one-on-one meetings.





**A<sup>e</sup>**  
*AltorferEngineering*

**AVANCE**  
EUROPE'S PREMIER LIFE SCIENCES  
ADVISORY BOUTIQUE

**BiOENgINEERING**

**CDR-Life**

**Cetacea**  
CONSULTING

**CLB**  
CHOOSE LIFE BIOTECH

**CYXONE**

**Floratek**  
pharma

**GALSER**

**LimmaTech**  
Biologics  
— better technology for better health —

**\$Maxia**  
STRATEGIES

**mbioproducts.**

**MV BioTherapeutics**

**NAGI**  
BIOSCIENCE

**NEW BIOLOGIX**

**Perseo**  
pharma®

**Promega**

**PSI**

**Sotio**

**ten 23**

**Trialize**


## Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (p. 35).

### Swiss Life's pension fund

With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.

**SWISS BIOTECH**'s Life



### Helvetia's business insurance


Our members can cover their business risks with Helvetia's individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.



**helvetia**   
Your Swiss Insurer

### LubioScience's portfolio

Our members benefit from special discounts on LubioScience's entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.



**LUBIO SCIENCE**  
THE REAGENT PLATFORM





### ProcEurope’s laboratory supplies

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific by the European Life Sciences Purchasing Consortium.



### BioCentury’s market research

A complimentary test access to BioCentury’s Intelligence platform, as well as discount on the subscription helps our members’ executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.



## BIOCENTURY

### Springer Nature’s leading publications

The world’s leading scientific and technical publisher Springer Nature offers our members’ subscription discounts between 25% and 50% for some of their most exciting products.



Springer Nature is excited to be part of Swiss Biotech Association. We're celebrating our partnership by offering introductory rates of 25-50% off to new subscribers for access to our most relevant content. Please find an overview of our product portfolio and sample pricing below. Pricing stated below is net. Your Contact at Springer Nature: **Beatrice Bourgoin**, Licensing Manager

## SPRINGER NATURE

# Swiss Biotech Association board and management

Thanks to new members joining our association, we have experienced substantial growth, allowing us to hire a dedicated team to oversee key vertical workgroups as talent and venture initiatives, but also to improve internal processes, build up international relations, and a representation for the Italian-speaking part of Switzerland. In short: More impact, more advancing our shared goals.

## The board

---



**Patrick Amstutz, PhD**  
President  
CEO Molecular Partners



**Luca Bolliger, PhD**  
Vice President  
CEO abcDNA



**Jurgi Camblong, PhD**  
Vice President  
CEO SOPHIA GENETICS



**Anne Marie de Jonge-Schuermans, PhD**  
Vice President  
Global Head Biologics & Injectables Operations  
Sandoz



**Bettina Ernst, PhD**  
Vice President  
CEO BERNINA Bioinvest



**Ulf Grawunder, PhD**  
Vice President  
Managing Partner  
Viopas Venture Consulting



**Filippo Riva**  
Vice President  
Managing Director,  
Humabs Biomed



## The management team

---




**Michael Altorfer, PhD**  
CEO



**Sabine Bamert**  
Head of communication



**Patrick Imwinkelried**  
Accounting  
Wespi & Partner



**Annamaria Kauzlaric**  
Member support



**Natasha Konstantinova**  
Head talent pool & Swiss  
Biotech Association  
Academy



**Maximilien Murone, PhD**  
Liaison Basel |  
Northwestern Switzerland



**Fabio Napoletano**  
Head business development  
Liaison Bern & Ticino



**Rachel Ougier Simonin**  
Business processes &  
IT infrastructure



**Tiziana Rosa, PhD**  
International relations &  
Liaison Svizzera Italiana



**Franz Waibel, PhD**  
Head Global Village



**Aditya Yellepeddi**  
Liaison Romandie |  
Western Switzerland

# Supporting the Swiss biotech hub: Objectives 2024

The 2024 objectives of the Swiss Biotech Association link to one of the four mission pillars (p. 11) or enhance the financial flexibility and operational effectiveness of the association.



## Favorable frameworks

Swiss biotech companies develop innovative products and new technologies for global medical needs. Therefore we need to aim to optimize the framework conditions on a global scale. E.g. international respect for intellectual property rights are crucial for viable investment in new drug and modality development. Without favorable frameworks, investors will not support such projects.

The Swiss Biotech Association has established a tight network of partners (p. 22) in Switzerland and abroad who are aligned and share a common objective to optimize global framework conditions for biotech startups and SMEs, focusing on R&D.

In 2024, we will focus on:

- Re-establishing Switzerland's full association with the Horizon Europe R&D program
- Opposing the proposed TRIPS (Trade Related Aspects of Intellectual Property Rights) waiver, which aims at weakening the international IP framework and thereby risks undermining biomedical innovation
- Reducing international differences in the approval process, the market exclusivity periods and the power of orphan drug designation, and fast track approvals
- Using our leading position in life sciences R&D to foster international collaboration and help innovate the global healthcare system in international alliances



## Talent and finance

The second pillar in our mission focuses on supporting Swiss-based biotech companies in accessing international talent, financial funding, and access to new technologies.

Attracting and retaining talent is key, as our industry is growing at a rate of 5-10% annually. This means that each year we need to attract an additional 2,000-3,000 biotech talents, while also replacing the people who retire.

On the finance side, Swiss biotech SMEs annually invest more than CHF 2 billion in R&D projects. While they generate some income through sales and milestone payments, they need to attract about CHF 1.5 billion in new funds from global investors to support the current size and growth rate of the industry.

In 2024, we support this mission pillar by:

- Promoting the Swiss Biotech Orbit platform (p. 9) to match talent and open job opportunities in Switzerland
- Expanding the partnerships bringing educational formats to our Academy platform
- Promoting our online Swiss Biotech Ventures platform (p. 8) which matches Swiss biotech ventures with global biotech investors and pharma partners
- Expanding the list of partnerships which offer business solutions that reduce operating costs for our members



## Networking and information exchange

Our flagship event, the Swiss Biotech Day, will again play a central role in fostering information exchange and providing national and international networking opportunities.

In 2024, we focus on ensuring the quality and diversity of the participants. In particular, we want to further increase the participation rate from global biotech investors, pharma partners and the core target group: Swiss-based biotech companies.

In 2024 we plan to strengthen networking opportunities by:

- Further growing the reach of the Swiss Biotech Day, including the embedded Global Village for international delegations
- Promoting international collaboration; connecting Swiss biotech talents with other biotech hubs to support know-how exchange and learn from best practices around the globe
- Expanding the Swiss R&D biotech, CFO, and HR meeting platforms which facilitate peer to peer know-how exchange and provide important feedback loops for the association
- Working closely with the Swiss Private Equity & Corporate Finance Association and Sachs Associates to exploit synergies with biotech investor meetings
- Launching a new association chapter for health tech companies to connect and support this rapidly expanding industry segment

## Promotion and awareness

For 13 consecutive years, Switzerland has led the global innovation index published by the World Intellectual Property Organization and the Swiss biotech hub is an important factor in this assessment.

The patent portfolio of Swiss biotech companies demonstrates that most of the innovative solutions are developed in close collaboration with international partners, as the Swiss biotech companies strive to help innovate the global healthcare system through international collaboration.

To promote the contribution and the value of the more than 1,400 Swiss-based biotech companies, remains the key objective of our fourth mission pillar. At the same time, we need to highlight the framework conditions required to enable these companies to continue to be an essential driver of Swiss innovation power.


To support this, in 2024 we will:

- Offer the digital and print edition of the Swiss Biotech Directory
- Publish the Swiss Biotech Report 2024, highlighting Switzerland's part in international collaboration and being a reliable partner beyond borders
- Present the Swiss Biotech Success Story Awards to the 2024 laureates
- Expand the partner network to support industry promotion and raise awareness of Swiss biotech accomplishments and needs



## Clear focus on what really matters

Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.



The strongly growing member base signals trust and affirm we're on the right track. A great motivation for the Swiss Biotech Association's board and management team!

We encourage continuing our active dialogue to jointly shape the future of the Swiss biotech hub and its framework, thereby keeping it on its successful track.

# SWISS BIOTECH <sup>TM</sup>

- Broaden your network, meet peers and investors
- Increase your impact and visibility
- Secure significant cost savings
- Capture new business and attract talent
- Collaborate with fellow members to strengthen the Swiss biotech hub

Join the Swiss Biotech Association



1 Nation 1 Biotech Cluster



Swiss Biotech Association  
Löwenstrasse 11  
8001 Zürich  
Switzerland

T: +41 44 455 56 78

[info@swissbiotech.org](mailto:info@swissbiotech.org)  
[swissbiotech.org](http://swissbiotech.org)